Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 7681 results

  1. Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]

    In development [GID-TA10930] Expected publication date: 28 May 2025

    Technology appraisal guidance
    In development

  2. Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]

    In development [GID-TA10620] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development [GID-TA10971] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  5. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development [GID-TA11228] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development [GID-TA11438] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development [GID-TA11402] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID 6460

    Awaiting development [GID-TA11534] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463

    Awaiting development [GID-TA11590] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994

      Status ...

    Technology appraisal guidance
    Topic selection

  12. Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]

    Awaiting development [GID-TA11467] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development [GID-TA11428] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]

    In development [GID-TA11164] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Duplicate

      Status ...

    Technology appraisal guidance
    Topic selection